Literature DB >> 1972623

mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles.

V Gekeler1, S Weger, H Probst.   

Abstract

Three high-level multidrug-resistant sublines of the human T-lymphoblastoid cell line CCRF-CEM were selected independently with either actinomycin D, vincristine or adriamycin. They exhibited distinct quantitative differences of cross-resistance profiles, and showed amplification and marked expression of the mdrl/P-glycoprotein gene. DNA and RNA were prepared from the cell lines, and additionally from three cell samples of patients suffering from acute lymphatic leukemia. Applying the polymerase chain reaction (PCR) for amplification, we cloned and sequenced from these sources segments of the mdrl/P-glycoprotein gene around the codon 185 which codes for an amino acid residue possibly influencing the drug binding function of the P-glycoprotein. Altogether, only 2 single nucleotide differences in an intron were found in 2 out of 40 recombinants each harboring a 209 bp genomic or a 269 bp cDNA fragment of the mdrl/P-glycoprotein gene. Our result does not support the idea of clustered point mutations in this segment of the P-glycoprotein gene as a cause of different multidrug resistance profiles. We additionally examined another segment of the P-glycoprotein gene in its second half, essentially delivering the same negative result, though.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972623     DOI: 10.1016/0006-291x(90)90401-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

Review 2.  The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells.

Authors:  L O'Driscoll; C Daly; M Saleh; M Clynes
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.

Authors:  Severin Mairinger; Thomas Wanek; Claudia Kuntner; Yaprak Doenmez; Sabine Strommer; Johann Stanek; Elena Capparelli; Peter Chiba; Markus Müller; Nicola A Colabufo; Oliver Langer
Journal:  Nucl Med Biol       Date:  2012-09-13       Impact factor: 2.408

Review 4.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

5.  Reversal of multidrug resistance by novel cyclosporin A analogues and the cyclopeptolide SDZ 214-103 biosynthesized in vitro.

Authors:  K Schwabe; G Steinheider; A Lawen; R Traber; A Hildebrandt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 6.  Modification of Glyceraldehyde-3-Phosphate Dehydrogenase with Nitric Oxide: Role in Signal Transduction and Development of Apoptosis.

Authors:  Vladimir I Muronetz; Maria V Medvedeva; Irina A Sevostyanova; Elena V Schmalhausen
Journal:  Biomolecules       Date:  2021-11-08

7.  Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.

Authors:  V Gekeler; G Frese; A Noller; R Handgretinger; A Wilisch; H Schmidt; C P Muller; R Dopfer; T Klingebiel; H Diddens
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

8.  Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.

Authors:  V Gekeler; R Boer; F Uberall; W Ise; C Schubert; I Utz; J Hofmann; K H Sanders; C Schächtele; K Klemm; H Grunicke
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

Review 9.  The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia.

Authors:  J A Holmes; R R West
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.